Hussman Strategic Advisors’s WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS WX Stock Holding History

Hussman Strategic Advisors’s Portfolio WX Stock Details WX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q1	–	Sell	-10,000	Closed	-$384K	–	226
2013 Q4	$384K	Sell	10,000 -10,000	-50%	-$316K	0.03%	160
2013 Q3	$548K	Sell	20,000 -20,000	-50%	-$474K	0.03%	151
2013 Q2	$840K	Buy	+40,000	New	+$781K	0.04%	159

Other funds holding WX

Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

CWAM

Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

CBOA

Commonwealth Bank of Australia Sydney, NSW, Australia $231M AUM

William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $299B AUM 28.69% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Hussman Strategic Advisors's WX Position: Q1 2014 in Review

Hussman Strategic Advisors sold out of WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS (WX) in Q1 2014, closing a stake of 10,000 shares — an estimated $384K sold.

Hussman Strategic Advisors first reported a position in WX in Q2 2013 and held it in 3 quarters. The position peaked at $840K in Q2 2013. 164 funds tracked by Wall St. Rank hold WX as of Q1 2014.

Hussman Strategic Advisors reported no remaining WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS position as of Q1 2014 after selling out during the quarter.
Hussman Strategic Advisors sold 10,000 WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS shares in Q1 2014, an estimated $384K.
Hussman Strategic Advisors first reported a position in WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS in Q2 2013 and held it in 3 quarters.
Hussman Strategic Advisors's WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS position peaked at $840K in Q2 2013.
164 funds tracked by Wall St. Rank held WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS as of Q1 2014.

Based on Hussman Strategic Advisors's 13F filing for Q1 2014, filed 1 May 2014.